Table 1.

Selected clinical trials of therapeutic vaccines against infectious disease

Therapeutic HPV vaccines
Vaccine type	Vaccine Formulation	Combination agents	Condition	Clinical trial identifier	Phase/status
Bacterial vector vaccine	ADXS11–001(attenuated live Listeria Encoding HPV 16 E7 vector)		Cervical carcinoma	NCT02164461	Phase I-II Completed
			Cervical carcinoma Head and Neck Cance	NCT02291055	Phase I-II Active, not recruiting
			Cervical cancer	NCT01266460	Phase II Completed
		Placebo	Cervical cancer	NCT02853604	Phase III Active, not recruiting
			Anal cancer Rectal cancer	NCT02399813	Phase II Completed
			Head and neck cancer, oropharyngeal squamous cell carcinoma	NCT02002182	Phase II Active, not recruiting
Viral vector vaccine	Vvax001(Semliki Forest virus expressing E6 and E7)		CIN 2/3 Cervical cancer	NCT03141463	Phase I Completed
	HB-201 (lymphocytic choriomeningitis virus encoding HPV E6 and E7)		HPV-Related Squamous Cell Carcinoma	NCT04180215	Phase I/II Recruiting
Peptide/protein vaccine	ISA101(nine HPV-16 E6 and four HPV-16 E7 synthetic peptides with Montanide ISA51)	Nivolumab	Solid Tumors	NCT02426892	Phase II Completed
	TVGV-1(HPV16 E7 fused protein +adjuvant GPI-0100)		High-grade squamous intraepithelial lesions	NCT02576561	Phase IIa Active, not recruiting
DNA vaccine	VGX-3100(plasmid encoding E6 and E7 of HPV16/18)		Head and neck squamous cell cancer	NCT02163057	Phase I/IIa Completed
			Cervical cancer	NCT02172911	Phase I/IIa Completed
		Placebo	High-grade squamous intraepithelial lesion of the cervix	NCT03185013	Phase III Completed
	GX188E (HPV E6/E7 fused to Flt3L		Cervical intraepithelial neoplasia	NCT02139267	Phase II Completed
		Placebo	Cervical Intraepithelial Neoplasia	NCT02596243	Phase II Active, not recruiting
			Cervical Intraepithelial Neoplasia 3	NCT03206138	Phase Ib/II Recruiting
Therapeutic HBV vaccines
Viral vector vaccines	TG1050(Adeno vector encoding core, polymerase, envelope fusion protein)	Placebo	Chronic HBV Infection	NCT02428400	Phase I/Ib Completed
Protein vaccine	Theravax (DV-601, consisting of HBsAg, HBcAg and saponin-based ISCOMATRIX adjuvant)	Entecavir	Chronic HBV Infection	NCT01023230	Phase IIb Completed
	GS-4774(Heat-inactivated yeast containing S, core, X proteins)		Chronic HBV Infection	NCT01943799	Phase II Completed
	GS-4774(Heat-inactivated yeast containing S, core, X proteins)	Tenofovir	Chronic HBV Infection	NCT02174276	Phase II Completed
	HeberNasvac (containing HBsAg and HBcAg)	Peg-IFN	Chronic HBV Infection	NCT01374308	Phase II Completed
	HeberNasvac (containing HBsAg and HBcAg)	NUC	Chronic HBV Infection	NCT02249988	Phase IIB-III Completed
	HepTcell vaccine (Synthetic peptide+ IC31 adjuvant)		Chronic HBV Infection	NCT02496897	Phase I Completed
DNA vaccine	INO-1800 (DNA plasmids encoding S and core)	NUC	Chronic HBV Infection	NCT02431312	Phase I Completed
	HB-110(a mixed plasmid DNA)	Adefovir	Chronic HBV Infection	NCT00513968	Phase I Completed
		Adefovir	Chronic HBV Infection	NCT01641536	Phase I Completed
Therapeutic HIV vaccines
DC-based vaccines	AGS-004(encoding the autologous HIV antigens Gag, Nef, Rev., and Vpr)	–	HIV Infection	NCT00672191	Phase II Completed
	HIV-1 ApB	–	HIV Infection	NCT00510497	Phase I/II Completed
mRNA vaccines	iHIVARNA (consisting of HIV immunogen sequence and a mixture of activation molecules (CD40L, CD70 and caTLR4))	–	HIV-infection	NCT02413645	Phase I Completed
		–	HIV-infection	NCT02888756	Phase IIa Terminated
Viral vector vaccines	MVA.HIVconsv(encoding 14 highly conserved regions of the viral proteome)	–	HIV-I infection	NCT01024842	Phase I Terminated
	HIVAX	–	HIV-infection	NCT01428596	Phase I
Therapeutic HCV vaccines
Yeast vector vaccine	GI-5005(expressing an NS3-core fusion protein)	–	HCV infection	NCT00124215	Phase I Completed
		–	HCV infection	NCT00606086	Phase II Completed
Viral vector vaccines	AdCh3NSmut/ Ad6NSmut (encoding HCV proteins)	–	HCV infection	NCT01094873	Phase I
	TG4040(expressing NS3/4/5B proteins)	–	HCV infection	NCT01055821	Phase I Completed

Source: The clinical trials were from ClinicalTrials.gov